---
title: "Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution"
description: Discover how PAI's Gene Therapy Stop-Loss Solution helps self-funded employers manage financial risks from million-dollar gene therapy claims.
---

[Insights ](https://email.paisc.com/pai_blogs)

# [Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution](https://email.paisc.com/pai_blogs/blog-post-0)

 Written by [Paisley Ann Ivey](https://email.paisc.com/pai_blogs/author/paisley-ann-ivey) | Mar 16, 2026 3:33:22 PM

### **Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution Employers Need Now**

Gene therapy is changing the way we think about healthcare and treatments for chronic diseases—and for **self‑funded employers**, it’s bringing serious financial shock potential. With many therapies priced between **$2 million and $4 million per treatment**, a single claim can throw an entire plan year off balance [1–4**]**. Additionally, as the number of **FDA‑approved** cellular and gene therapies keeps climbing, traditional stop‑loss coverage isn’t built to handle this level of volatility anymore [5, 6].

That’s why **Planned Administrators, Inc. (PAI)**—in partnership with **SBR** and the **Association for CGT Solutions**—created a purpose‑built **Gene Therapy Stop‑Loss Solution**. It’s designed to take the guesswork (and sticker shock) out of million‑dollar claims by helping employers:

- Avoid catastrophic financial surprises [7]
- Stabilize renewals year over year [8]
- Gain real predictability in a rapidly changing market [9]

In short, it’s the protection self‑funded employers need as gene therapy becomes more common—and far more expensive [5].

### **Gene Therapy Outcomes: High‑Impact, High‑Risk**

Gene therapies are delivering **life‑changing outcomes** for conditions that once had no real treatment options, but the price tags are just as dramatic [5].

Industry forecasts suggest **U.S. gene therapy spend could reach ~$18.5B by 2033** [10, 11]. As more therapies make it through the **FDA** pipeline, employer exposure grows—often without the historical claims data on which underwriters rely [5, 6].

That creates a tough reality for self-funded health plans:

- Claims are  infrequent, but financially overwhelming [12]
- Timing is unpredictable [8]
- A single event can disrupt renewals for years [8]

In other words, gene therapy brings incredible clinical value, but also unprecedented — and unpredictable — financial risk[ 5].

### **The Real Cost of Gene Therapy: What Employers Are Actually Facing**

For self‑funded employers, the true **cost of gene therapy** goes far beyond the drug’s list price. While these treatments offer incredible clinical benefits, they also come with **high‑cost claims** that can overwhelm traditional stop‑loss coverage, and total exposure often rises when facility fees, conditioning/administration, and care coordination are included [13].

**Real‑world price points (therapy list/WAC):**

- **Zolgensma® (SMA):** ~**$2.1–$2.3M** for the therapy [1, 14].
- **Skysona® (CALD):** ~**$3.0M** for the therapy [2, 15].
- **Hemgenix® (Hemophilia B):** up to **~$3.5M** for the therapy [3, 16].
- **Casgevy® (SCD/****β****‑thal):** ~**$2.2M** for the therapy [4, 17].

**Note on administration/ancillary costs:** Exact amounts vary by site of care, protocol, and patient factors; plans should expect **additional six‑figure costs** in many cases. [13].

Bottom line: **gene therapy claims can exceed traditional stop‑loss thresholds quickly**, reshaping a plan’s financial trajectory and impacting renewal pricing [8, 6].

### **Why Traditional Stop‑Loss Is No Longer Enough**

Stop‑loss insurance is still a critical safety net for self‑funded employers—but the rise of **gene therapy and other ultra‑high‑cost claims** has exposed serious gaps in traditional models [8].

Here’s what today’s market data makes clear:

1. ** Gene therapy costs are outpacing historical models**

High‑cost claims are now blowing past deductibles, because most of these therapies are new, **there’s no historical data** to guide accurate underwriting. Carriers are being forced to **price forward**, building assumptions into renewals that may or may not match actual risk [6].

1. ** Million‑dollar claims are no longer rare**

Specialty medications, orphan drugs, and FDA‑approved gene therapies are all driving a sustained rise in **$1 million+ claims [12]**.

1. ** Renewal volatility is hitting employers hard**

After a catastrophic claim—or even the *potential* for one—stop‑loss premiums can spike dramatically. This makes **budgeting unpredictable**, especially for mid‑sized and self‑funded employers trying to maintain plan stability [8].

**What’s needed now:** a **gene‑therapy‑ stop‑loss solution** built specifically to handle the speed, scale, and financial impact of million‑dollar CGT claims [7, 18].

### ****A Smarter Gene Therapy Stop‑Loss Strategy:**

PAI + SBR’s CGT Solution**

The **Comprehensive Gene Therapy (CGT) Solution** from PAI and SBR is built specifically to manage the financial exposure tied to gene therapy claims—one of the fastest‑growing and most unpredictable cost categories for self‑funded employers.

**2026 Program Cost: $4.05 PEPM **(eligibility, underwriting, and program terms apply) [20].   
This fixed PEPM rate provides straightforward, predictable protection against multimillion‑dollar CGT claims, helping stabilize budgets and reduce renewal volatility [7].

### **How the CGT First‑Dollar Stop‑Loss Model Works**

The CGT Solution uses a **first‑dollar coverage** structure, which means protection kicks in **from the start** of a covered gene therapy claim [7].

Here’s how the process works:

**Step 1: The plan incorporates a pre-treatment provision into their plan document with contact information for a designated CGT Program Manager.**

When a covered gene therapy is anticipated the rendering provider contacts the CGT Program manager and a pre-treatment review is completed.

**Step2: The CGT Program Manager responds**

Coordination of care through a Center of Excellence (COE) provider designated by the CGT Program Manager.

**Step 3: The ACGT Reinsurance Program reimburses **

The ACGT Reinsurance Program steps in and reimburses:

**The plan **for claims paid **up to the specific fee scheduled amounts noted in the ACGT reinsurance policy. The end result: **catastrophic gene therapy exposure is mitigated** before** it impacts the employer’s balance sheet [7].

### **Beyond Reimbursement: Integrated Clinical & Administrative Support**

When a candidate for gene therapy case is identified—**whether covered or not**—PAI and SBR provide hands‑on support to brokers, employers, and members:

- Coordination with **credentialed Centers of Excellence**
- Therapy and administration review
- Help with **eligibility, adjudication, and early engagement**
- Efforts to reduce cost impact for the plan and the member
- Access to **patient navigation** experienced in rare/complex conditions

If the reinsurance program covers the therapy, **early identification of candidates, review and oversight** must begin immediately, helping streamline the process, prevent delays, and avoid downstream disruption for the employer and member [13].

### **Integration With Captives and Reinsurance Structures**

For employers using **captive insurance** or **reinsurance**, the CGT Solution fits smoothly into **layered risk models.** This flexibility becomes especially important when **gene therapy claims can exceed $2.5 million** [8]. Distributing risk across multiple layers, employers can reduce financial shock, protect captive performance, and maintain long‑term plan stability [6].

### **Why Employers Must Act Before Renewal Season**

FDA‑approved gene therapies are increasing every year and stop‑loss underwriting is shifting just as quickly. Carriers are now **pricing ahead of utilization**, renewals are becoming harder to predict, and employers without CGT-specific protection face growing exposure [21, 6]

Proactively adopting **gene therapy reinsurance coverage** helps employers:

- Prevent **renewal shock** [8]
- Reduce **laser** risk [18]
- Protect employee access to high‑value therapies [11]
- Stabilize **long‑term** plan costs [8]

Waiting for the first claim is no longer a workable approach [8], early adoptionon a pre-service basis for a potential candidate is the only way to stay ahead of rapidly rising gene therapy risk.

### **Final Takeaway**

Gene therapy is changing the landscape of catastrophic claims. But with **PAI’s administrative expertise**, **SBR’s CGT Solution**, and support from the **Association for CGT Solutions**, employers finally have a **gene‑therapy‑specific** stop‑loss strategy built for today’s cost and risk realities [19, 22].

You don’t have to absorb the impact. You can prevent it.

### **Ready to Protect Your Plan?**

**→**** Learn More About the Gene Therapy Stop‑Loss Solution**  
[**→**** Connect With PAI **](mailto:marketing@paisc.com)

**Footnotes**

1. Drugs.com. “Why is Zolgensma so expensive?” (Last updated Sept 4, 2024). [Link](https://www.drugs.com/medical-answers/zolgensma-expensive-3552644/)
2. Ambiom. “The 4 most expensive single-dose drugs in 2022” (Nov 13, 2022) — Skysona priced at ~$3.0M. [Link](https://ambiom.com/the-4-most-expensive-single-dose-drugs-in-2022)
3. Drugs.com. “Why is Hemgenix so expensive? … priced at $3.5M per dose.” (Last updated Nov 17, 2025). [Link](https://www.drugs.com/medical-answers/hemgenix-expensive-drug-world-3573635/)
4. BioPharma Dive. “Casgevy … will cost $2.2 million.” (Dec 8, 2023). [Link](https://www.biopharmadive.com/news/crispr-sickle-cell-price-millions-gene-therapy-vertex-bluebird/702066/)
5. U.S. FDA. “Approved Cellular and Gene Therapy Products” (live list). [Link](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products)
6. Lockton. “Medical stop loss – PS Market Update 2025 Q3.” (2025). [Link](https://insights.lockton.com/people-solutions-market-update/q3-2025/medical-stop-loss)
7. Amwins. “Gene Therapy Solutions” — first‑dollar protection and integration with stop‑loss. [Link](https://www.amwins.com/solutions/group-benefits/self-funded/cost-containment/gene-therapy-solutions)
8. QBE. “2025 Accident & Health Market Report” — renewal volatility & $1M+ claims dynamics. [Link](https://www.qbe.com/media/qbe/north-america/usa/files/accident-health/2025-ah-market-report.pdf)
9. Oliver Wyman/Guy Carpenter. “Stop‑Loss Market Update” summary—data/AI and portfolio pressure. (2025). [Link](https://www.oliverwyman.com/our-expertise/insights/2025/sep/stop-loss-2025-trends-cost-claims-ai-strategy.html)
10. BioSpace/NovaOne press note. “U.S. gene therapy market … to hit USD 18.50B by 2033.” (Feb 26, 2025). [Link](https://www.biospace.com/press-releases/u-s-gene-therapy-market-size-to-hit-usd-18-50-billion-by-2033)
11. Nova One Advisor (reported by BioSpace), “U.S. Gene Therapy Market Size, Share & Growth Report, 2033” (Apr. 12, 2024). [Link](https://www.biospace.com/u-s-gene-therapy-market-size-share-and-growth-report-2033)
12. Sun Life. “2025 High‑Cost Claims and Injectable Drug Trends Report.” (2024/2025). [Link](https://view.ceros.com/sun-life/high-cost-claims-and-injectable-drugs-report)
13. Mercer. “Employers’ top four questions about cell and gene therapies” — admin/procedural components & navigation. (Aug 13, 2025). [Link](https://www.mercer.com/en-us/insights/us-health-news/employers-top-four-questions-about-cell-and-gene-therapies/)
14. Summit Re. “Gene Therapy Summary 2019–2024” — Zolgensma WAC noted ~$2.322M. (Feb 27, 2025). [Link](https://www.summit-re.com/blog/2025/2/27/gene-therapy-summary-2019-2024-from-a-reinsurancestop-loss-perspective)
15. Pharmacy Times. “Clinical Overview: Skysona …” (Nov 10, 2022). [Link](https://www.pharmacytimes.com/view/clinical-overview-skysona-for-early-cerebral-adrenoleukodystrophy)
16. MDLinx. “$3.5 million blood‑clotting shot … Hemgenix.” (Dec 13, 2022). [Link](https://www.mdlinx.com/article/this-3-5-million-blood-clot-shot-has-been-approved-by-the-fda/4sPfj2uNzVrGUtp11V63Hj)
17. AAFP Blog. “Will the High Price of Gene Therapy for SCD Put This Cure out of Reach?” (Dec 12, 2023). [Link](https://www.aafp.org/pubs/afp/afp-community-blog/entry/will-the-high-price-of-gene-therapy-for-sickle-cell-disease-put-this-cure-out-of-reach.html)
18. CVS Health / Aetna. “Providing financial protection from the impact of high‑cost gene therapies” (Gene Therapy Stop‑Loss Executive Summary). (2024). [Link](https://business.caremark.com/content/dam/enterprise/business-caremark/insights/pdfs/2024/gene_therapy_stop_loss_solution_executive_summary.pdf)
19. PAI – “Cell and Gene Therapy (CGT)” program/insights page. [Link](https://www.paisc.com/insights/cell-and-gene-therapy-cgt)
20. BCS Financial. “Now Quoting Gene Therapy Stop Loss for 2026.” (Sept 9, 2025). (PEPM example for market context). [Link](https://bcsf.com/blog/now-quoting-gene-therapy-stop-loss-for-2026/)
21. PharmaBoardroom. “FDA Cell & Gene Therapy Approvals 2024.” (May 8, 2025). [Link](https://pharmaboardroom.com/articles/fda-cell-gene-therapy-approvals-2024/)
22. Association for CGT Solutions (ACGTS) — organization site & program overview. [Link](https://cgtsolutions.com/)

[View full post](https://email.paisc.com/pai_blogs/blog-post-0)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Paisley Ann Ivey"
  },
  "dateModified" : "2026-03-16T15:43:59.909Z",
  "datePublished" : "2026-03-16T15:33:22Z",
  "headline" : "Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1024,
    "url" : "https://45524766.fs1.hubspotusercontent-na1.net/hubfs/45524766/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%20office%20setting%20with%20a%20sleek%20conference%20table%20at%20the%20center%20surrounded%20by%20highbacked%20ergonomic%20chairs%20On%20the%20table%20a%20large%20d.png",
    "width" : 1024
  },
  "mainEntityOfPage" : "https://email.paisc.com/pai_blogs/blog-post-0",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Insights"
  }
}
```